IBDoc News

IBDoc® is present in the market for 6 years now and its efficiency and usefulness has been described many times by different research teams all over the world (1, 2, 3). All of these papers are evaluating IBDoc® as a stand-alone product but IBDoc® has the possibility to be integrated in a 3rd party application,

In 2020, the COVID-19 crisis had a high impact on the daily life of people all over the world. That is particularly true for patients with a chronic disease who must go to their hospital for regular follow-up visits. Inflammatory Bowel Disease (IBD) patients are no exception here. In order to face this extraordinary situation,

In 2016, the Nancy University Hospital has set-up a virtual clinic for Inflammatory Bowel Disease (IBD) patients. The main goal of this eHealth solution is to provide a communication channel between patients and the healthcare professionals and to decide on patient management changes. In 2018, the IBD unit decided to add the possibility to perform

Fecal calprotectin is an ideal non-invasive marker to monitor inflammation in the gut for patients suffering from IBD. Since IBD is a chronic condition, remote disease monitoring offers patients to facilitate their disease management and working lives since less hospital visits are needed. Further, hospital visits always bear the risk of potential infections, not only

At ECCO 2020, IBDoc® was again under the spotlight as 2 very interesting posters were presented. After 5 years of market presence, long term data about the impact of IBDoc® usage in clinical routine are beginning to emerge. Improving quality of life of IBD patients is extremely important, developing tools to allow patients to have

Worldwide more than 6.8 million people live with Inflammatory Bowel Disease (IBD) which is characterized by chronic inflammation of the gastrointestinal tract. The highest numbers of IBD patients are observed in North America and Europe with an estimated 2.2 million affected persons in North America and an estimated 0.3% of the European population suffering from

Because of the current situation with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the COVID-19 disease it is important to keep IBD patients out of clinics whenever possible. Nevertheless, tight monitoring of inflammation level in the gut is needed to deal with these chronic conditions. Calprotectin has proven to be an ideal

The use of fecal calprotectin (fCAL) in clinical routine is demonstrated beyond doubt. We now have extensive knowledge of its efficacy for IBD/IBS differentiation and IBD monitoring, as it has been shown to be an excellent surrogate biomarker for inflammatory status of the gut that correlates well with endoscopic activities (1). The key benefit of

Allô docteurs is a French medical TV show, covering new topics every day to help patients dealing with their disease. On the 3rd of February 2020, the show was  about “living with IBD”. A 3 minute story was presented on how healthcare professionals and patients are using IBDoc®, the fecal calprotectin home test, to improve

New IBDoc® Tutorial Videos We created six new IBDoc® Portal Tutorial Videos. They help Healthcare Professionals that start using IBDoc® with the first steps of creating an account and setting up new users. Visit www.ibdoc.net for all Tutorial Videos Updated IBDoc® Flyer This flyer can be used to easily demonstrate the efficiency and practicality of IBDoc®.